Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous ...

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.

CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response

Newly released preclinical data to be presented in a poster on November 8, 2025SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- ...

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...
Climate Compass on MSN

How Ocean Currents Affect The Climate - Described By Climate Scientists

The Ocean's Global Heat Distribution System One of the most important functions of the ocean is to move heat around the ...
Psychology Today

What Cell Phone Bans Mean for Students

In public schools across the country, states are implementing "bell-to-bell" cell phone bans—policies that restrict ...

New Phase 2 Data for Aulos Bioscience's Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...
Agence France-Presse

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary ...

Pove was generally safe and well tolerated with adverse events (AEs) that were mostly mild or moderate in severity. There were no serious adverse events related to povetacicept. The safety data is ...